Kory James Wentworth, Chief Financial Officer at Entrada Therapeutics, Inc. (TRDA), sold 1,376 shares at $14.03 ($19K) on 2023-09-06, disclosed to the SEC on 2023-09-06.
Scheduled sale ($19k) by Chief Financial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $14.46 | 426 | $6K | 32.5% |
| 2 | $13.45 | 904 | $12K | 64.1% |
| 3 | $14.03 | 46 | $645 | 3.4% |
| Total | $13.78 avg | 1,376 | $19K | 100% |
| Filing → |
| TRDA | SELL | 2026-03-06 | $196K | — | Filing → |
| TRDA | SELL | 2025-11-24 | $178K | — | Filing → |
| TRDA | SELL | 2025-03-19 | $19K | — | Filing → |